JP2010536396A - タンパク質力価を増加させる方法 - Google Patents

タンパク質力価を増加させる方法 Download PDF

Info

Publication number
JP2010536396A
JP2010536396A JP2010522371A JP2010522371A JP2010536396A JP 2010536396 A JP2010536396 A JP 2010536396A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010536396 A JP2010536396 A JP 2010536396A
Authority
JP
Japan
Prior art keywords
protein
antibody
cells
cell
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536396A5 (enExample
Inventor
ドロテー アムブロジウス
バーバラ エネンケル
クリシュティアン エッカーマン
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2010536396A publication Critical patent/JP2010536396A/ja
Publication of JP2010536396A5 publication Critical patent/JP2010536396A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010522371A 2007-08-29 2008-08-28 タンパク質力価を増加させる方法 Pending JP2010536396A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115227A EP2031064A1 (de) 2007-08-29 2007-08-29 Verfahren zur Steigerung von Proteintitern
PCT/EP2008/061310 WO2009027471A1 (de) 2007-08-29 2008-08-28 Verfahren zur steigerung von proteintitern

Publications (2)

Publication Number Publication Date
JP2010536396A true JP2010536396A (ja) 2010-12-02
JP2010536396A5 JP2010536396A5 (enExample) 2011-10-13

Family

ID=39107125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522371A Pending JP2010536396A (ja) 2007-08-29 2008-08-28 タンパク質力価を増加させる方法

Country Status (6)

Country Link
US (1) US20100297697A1 (enExample)
EP (2) EP2031064A1 (enExample)
JP (1) JP2010536396A (enExample)
KR (1) KR20100046219A (enExample)
CA (1) CA2696809A1 (enExample)
WO (1) WO2009027471A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526884A (ja) * 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2016512508A (ja) * 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2018528214A (ja) * 2015-09-01 2018-09-27 オンコクール・エムエル・ゲーエムベーハー コイルドコイルコネクタ
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2021519754A (ja) * 2018-03-30 2021-08-12 アムジエン・インコーポレーテツド Ｃ末端抗体改変体

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) * 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
WO2013009648A2 (en) 2011-07-08 2013-01-17 Momenta Pharmaceuticals, Inc. Cell culture process
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013160316A1 (en) * 2012-04-23 2013-10-31 Dsm Ip Assets B.V. Polypeptide expression method
WO2013164694A1 (en) * 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3350226A2 (en) 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
PE20210042A1 (es) 2017-10-06 2021-01-08 Prothena Biosciences Ltd Metodos para detectar transtiretina
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3877410A4 (en) 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
AU2019386976B2 (en) 2018-11-26 2024-05-30 Forty Seven, LLC Humanized antibodies against c-Kit
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
EP3995582B1 (en) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
US20240010735A1 (en) 2020-12-24 2024-01-11 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
JP7796049B2 (ja) 2020-12-24 2026-01-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
AU2022388189A1 (en) 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
AR133829A1 (es) 2023-09-15 2025-11-05 Othair Prothena Ltd Agentes penetrantes de células y usos de los mismos
AU2024341846A1 (en) 2023-09-15 2026-04-23 Prothena Biosciences Limited Cell penetrating agents and uses thereof
WO2025059491A2 (en) 2023-09-15 2025-03-20 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
TW202530253A (zh) 2023-09-15 2025-08-01 愛爾蘭商普羅希那生物科學有限公司 抗ｔｄｐ－４３抗體及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163096A (ja) * 1988-09-28 1990-06-22 Eli Lilly & Co モノクローナル抗体の不均質性を減少させる方法
JP2004536580A (ja) * 2001-04-13 2004-12-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対する抗体
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163096A (ja) * 1988-09-28 1990-06-22 Eli Lilly & Co モノクローナル抗体の不均質性を減少させる方法
JP2004536580A (ja) * 2001-04-13 2004-12-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対する抗体
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013026613; ＰＡＲＡＭＰＡＬＬＩ，　Ａ．　ｅｔ　ａｌ．: '"Ｄｅｖｅｌｏｐｅｍｅｎｔ　ｏｆ　ｓｅｒｕｍ-ｆｒｅｅ　ｍｅｄｉａ　ｉｎ　ＣＨＯ-ＤＧ４４　ｃｅｌｌｓ　ｕｓｉｎｇ　ａ　ｃｅｎｔｒａｌ　ｃｏｍｐｏｓｉｔｅ　ｓｔａｔｉｓｔｉｃａｌ　ｄｅｓｉｇｎ．"' ＣＹＴＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．５４，　Ｎｏ．１, 200705, Ｐ．５７-６８ *
JPN6013026616; ＫＡＮＤＡ，　Ｙ．　ｅｔ　ａｌ．: '"Ｅｓｔａｂｌｉｓｈｍｅｎｔ　ｏｆ　ａ　ＧＤＰ-ｍａｎｎｏｓｅ　４，６-ｄｅｈｙｄｒａｔａｓｅ　（ＧＭＤ）　ｋｎｏｃｋｏｕｔ　ｈｏｓｔ　ｃｅｌｌ　ｌｉｎｅ：　ａ　ｎｅｗ　ｓｔｒａｔｅｇｙ　ｆｏｒ　ｇｅ' ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．１３０，　Ｎｏ．３, 20070630, Ｐ．３００-３１０ *
JPN7013002069; ＴＡＫＡＩ，　Ｔ．　ｅｔ　ａｌ．: '"Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｈｕｍａｎｉｚｅｄ　Ｆａｂ　ｆｒａｇｍｅｎｔｓ　ｔｈａｔ　ｒｅｃｏｇｎｉｚｅ　ｔｈｅ　ＩｇＥ-ｂｉｎｄｉｎｇ　ｄｏｍａｉｎ　ｏｆ　ｈｕｍａｎ　Ｆｃ（ｅｐｓｉｌｏｎ）ＲＩａ' ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１２９，　Ｎｏ．１, 200101, Ｐ．５-１２ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019000116A (ja) * 2011-07-06 2019-01-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2014526884A (ja) * 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2016512508A (ja) * 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2019010111A (ja) * 2013-03-12 2019-01-24 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
US11090381B2 (en) 2015-09-01 2021-08-17 Oncoqr Ml Gmbh Coiled-coil connector
JP2018528214A (ja) * 2015-09-01 2018-09-27 オンコクール・エムエル・ゲーエムベーハー コイルドコイルコネクタ
JP2021519754A (ja) * 2018-03-30 2021-08-12 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
US11858983B2 (en) 2018-03-30 2024-01-02 Amgen Inc. C-terminal anti-sclerostin antibody variants
JP2024037881A (ja) * 2018-03-30 2024-03-19 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
JP7747715B2 (ja) 2018-03-30 2025-10-01 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
US12570734B2 (en) 2018-03-30 2026-03-10 Amgen Inc. C-terminal anti-sclerostin antibody variants

Also Published As

Publication number Publication date
KR20100046219A (ko) 2010-05-06
WO2009027471A1 (de) 2009-03-05
EP2031064A1 (de) 2009-03-04
US20100297697A1 (en) 2010-11-25
CA2696809A1 (en) 2009-03-05
EP2195431A1 (de) 2010-06-16

Similar Documents

Publication Publication Date Title
US20100297697A1 (en) Methods for increasing protein titers
JP5481478B2 (ja) 新規調節エレメント
US9243053B2 (en) Heterologous intron within an immunoglobulin domain
EP2938728B1 (en) Artificial introns
US20140248665A1 (en) Novel intron sequences
EP2938726B1 (en) Heterologous intron within a signal peptide
JP7826509B2 (ja) 選択マーカーとしての新規グルタミン合成酵素変異体
JP2025510718A (ja) 哺乳動物細胞における選択マーカーとしての細菌グルタミン合成酵素
US20110014624A1 (en) Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
HK1156663B (en) Novel regulatory elements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105